

Special Issue

Development of Antiprotozoal Drugs

Message from the Guest Editors

Protozoan parasites that are infectious to humans represent a significant threat to health and cause more than one million deaths annually. They also threaten the lives of billions of individuals worldwide and are associated with significant morbidity and large economic impacts. The significant burden of human protozoan infections has been exacerbated by the lack of effective vaccines for any of the diseases caused by these parasites. Treatment and prophylaxis have, therefore, been dependent on drugs, many of which have become less effective, necessitating the search for replacements. This Special Issue of *Microorganisms* will collect relevant articles that report on recent advances in antiparasitic research, from basic to translational studies. We invite your contributions, either in the form of original research or review articles, covering various aspects of research into new therapies, including molecular and cell biology, physiology and the development of new drug combinations or formulations.

Keywords

- drug discovery
- chemotherapy
- parasite
- protozoa
- formulations
- combined therapy

Guest Editors

Dr. Atteneri López Arencibia

Departamento de Obstetricia y Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, San Cristóbal de La Laguna, Spain

Dr. Ines Sifaoui

Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Francisco Sánchez s/n, Campus de Anchieta, 38203 La Laguna Tenerife, Canary Islands, Spain

Deadline for manuscript submissions

closed (15 March 2024)



Microorganisms

an Open Access Journal
by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/126798

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

[mdpi.com/journal/
microorganisms](https://mdpi.com/journal/microorganisms)





Microorganisms

an Open Access Journal
by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
microorganisms](https://mdpi.com/journal/microorganisms)



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2025).